Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $7.83M |
| Net Income (Most Recent Fiscal Year) | $-64.92M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 93.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.20 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -921.50% |
| Net Margin (Trailing 12 Months) | -921.50% |
| Return on Equity (Trailing 12 Months) | -61.65% |
| Return on Assets (Trailing 12 Months) | -42.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.46 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.46 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.85 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.58 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 139.82M |
| Free Float | 133.11M |
| Market Capitalization | $772.53M |
| Average Volume (Last 20 Days) | 2.10M |
| Beta (Past 60 Months) | 0.79 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.34% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |